HC Wainwright Has Bearish Estimate for Myomo Q4 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Analysts at HC Wainwright cut their Q4 2025 earnings per share (EPS) estimates for shares of Myomo in a research note issued on Tuesday, November 11th. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($0.08) per share for the quarter, down from their prior forecast of ($0.02). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.15) EPS and FY2028 earnings at $0.07 EPS.

Separately, Ascendiant Capital Markets lowered their price target on shares of Myomo from $11.50 to $10.50 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $7.83.

Myomo Stock Performance

Shares of Myomo stock traded down $0.02 during trading on Thursday, reaching $0.83. The company’s stock had a trading volume of 268,092 shares, compared to its average volume of 936,699. Myomo has a fifty-two week low of $0.79 and a fifty-two week high of $7.17. The firm has a market cap of $31.79 million, a PE ratio of -2.85 and a beta of 1.48. The company has a current ratio of 2.49, a quick ratio of 2.03 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average price of $0.97 and a two-hundred day moving average price of $1.93.

Insider Transactions at Myomo

In other Myomo news, CEO Paul R. Gudonis bought 50,000 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were acquired at an average cost of $0.95 per share, with a total value of $47,500.00. Following the completion of the transaction, the chief executive officer owned 1,259,013 shares in the company, valued at $1,196,062.35. The trade was a 4.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas F. Kirk purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $1.15 per share, with a total value of $57,500.00. Following the purchase, the director owned 474,420 shares of the company’s stock, valued at approximately $545,583. The trade was a 11.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 150,000 shares of company stock valued at $160,000. Insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On Myomo

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Summit Financial Strategies Inc. increased its stake in shares of Myomo by 50.0% during the second quarter. Summit Financial Strategies Inc. now owns 15,000 shares of the company’s stock valued at $32,000 after acquiring an additional 5,000 shares during the period. Engineers Gate Manager LP lifted its position in Myomo by 62.8% during the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after acquiring an additional 11,614 shares during the last quarter. R Squared Ltd bought a new stake in Myomo in the 2nd quarter valued at $29,000. Dynamic Technology Lab Private Ltd acquired a new stake in Myomo during the first quarter worth $75,000. Finally, Invesco Ltd. bought a new stake in Myomo in the second quarter valued at $37,000. 44.99% of the stock is owned by institutional investors.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.